Eli Lilly will apply for approval of an obesity drug that a late-stage study showed can slash a person’s body weight by almost a sixth, raising hopes for a new blockbuster treatment to tackle the global obesity epidemic.
The US drugmaker said on Thursday that a high dose of its drug Tirzepatide helped people who have type 2 diabetes and are overweight or obese lose on average almost 16 per cent of their body weight, or 15.6 kilogrammes, over almost 17 months.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased